Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Laekna Raises $100 Million in Hong Kong IPO for Cancer, Liver Fibrosis Inhibitors

publication date: Jun 29, 2023

Shanghai Laekna Therapeutics completed an IPO on the Hong Kong Exchange that raised $100 million for its portfolio of biologic therapies. The shares traded 20% higher in its first trading day. Founded in 2016, the company has a portfolio consisting of two core products, both in-licensed from Novartis, plus 14 other pre-clinical candidates aimed at cancer and liver fibrosis. It has started six clinical trials for its two lead projects, including three multi-regional studies, one of which is a pivotal trial. The company will use the funds to advance its portfolio and build a manufacturing facility. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital